Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
satraplatin + prednisone
- Development stage
- Discontinued
- Lead developer
- GPC Biotech
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Satraplatin + prednisone is an investigational oral combination therapy primarily evaluated for the treatment of hormone-refractory prostate cancer (HRPC), also known as castration-resistant prostate cancer (CRPC). Satraplatin is a third-generation oral platinum(IV) compound that functions as a DNA-damaging agent—when cellular uptake occurs, it forms DNA adducts and cross-links, disrupting DNA synthesis and replication, ultimately inducing apoptosis. Prednisone is a corticosteroid with anti-inflammatory and immunosuppressive effects, and in the context of prostate cancer, it provides palliative benefits and may enhance chemotherapeutic efficacy. Clinical trials have demonstrated that the combination results in a statistically significant improvement in PSA responses and progression-free survival versus prednisone alone in patients with HRPC; overall survival, however, was not significantly extended, leading to discontinuation of large-scale development. Toxicity was generally mild. Both drugs are administered orally[1][2][3][4][6].
- Other names
- satraplatin + prednisone
02
Targets
DNAGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on satraplatin + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on satraplatin + prednisone.